|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
7/31/2012 7:39:30 AM
In April 2012, Kevin Middleton left his position as head of sales for the Teva Pharamceutical specialty sales force, where he oversaw promotion for such neuroscience meds as the Copaxone multiple sclerosis treatment. As part of his departure, he signed a separation agreement that prevented him from soliciting other Teva employees for up to one year. But within two months of leaving Teva, he went to work for Genzyme and allegedly began soliciting former colleagues to join him. In doing so, Middleton allegedly transferred confidential info about Copaxone to Genzyme, which was preparing to compete in the MS marketplace, in violation of his separation agreement, according to a lawsuit that Teva filed against Middleton and Genzyme, which is now owned by Sanofi, in federal court in Philadelphia.
|
|
|
|
|
|
|
|
|
|
|